Literature DB >> 9022624

Ability of an anti-luteinizing hormone-releasing hormone vaccine to inhibit gonadotropins in postmenopausal women.

C Gual1, J Garza-Flores, M Menjivar, A Gutierrez-Najar, R Pal, G P Talwar.   

Abstract

OBJECTIVE: To determine the effects of immunization with an anti-LH-releasing hormone (LH-RH) vaccine in postmenopausal women.
DESIGN: Pilot clinical study.
SETTING: Normal human volunteers in a medical research-training environment. PATIENT(S): Three postmenopausal women with a mean age of 60 years, 5 years of amenorrhea, and severe hypoestrogenism with elevated serum LH and FSH. INTERVENTION(S): Intramuscular immunization with 300 micrograms LH-RH equivalent of the vaccine in two occasions 1 month apart. MAIN OUTCOME MEASURE(S): Patients were followed for clinical assessment and serum LH, FSH, and anti-LH-RH titers at regular monthly intervals for 7 months. RESULTS(S): The injection of the anti-LH-RH vaccine followed by a booster injection 1 month later resulted in a sharp decrease, 60 days after the first injection, of both serum gonadotropins, accompanied by an increase in anti-LH-RH antibody titers, which were reversible after 180 days in the absence of further booster immunization. CONCLUSION(S): Active immunization offer a safe option to induce antibody response, which in the present regime employed was of about 6-months duration. This procedure opens new possibilities for its use as an affordable therapeutic agent in some hormone-dependent clinical conditions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9022624     DOI: 10.1016/S0015-0282(97)81932-2

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  2 in total

1.  Anti-GnRH antibodies can induce castrate levels of testosterone in patients with advanced prostate cancer.

Authors:  M S Simms; D P Scholfield; E Jacobs; D Michaeli; P Broome; J E Humphreys; M C Bishop
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

2.  Safety and Therapeutic Profile of a GnRH-Based Vaccine Candidate Directed to Prostate Cancer. A 10-Year Follow-Up of Patients Vaccinated With Heberprovac.

Authors:  Jesús A Junco; Ranfis Rodríguez; Franklin Fuentes; Idania Baladrón; Maria D Castro; Lesvia Calzada; Carmen Valenzuela; Eddy Bover; Eulogio Pimentel; Roberto Basulto; Niurka Arteaga; Angel Cid-Arregui; Francisco Sariol; Lourdes González; Liliana Porres-Fong; María Medina; Ayni Rodríguez; A Hilda Garay; Osvaldo Reyes; Matilde López; Lourdes de Quesada; Allelin Alvarez; Carolina Martínez; Marleny Marrero; Guillermo Molero; Alfredo Guerra; Pedro Rosales; Carlos Capote; Sahily Acosta; Idania Vela; Lina Arzuaga; Ana Campal; Erlán Ruiz; Elier Rubio; Pável Cedeño; María Carmen Sánchez; Pedro Cardoso; Rolando Morán; Yairis Fernández; Magalys Campos; Henio Touduri; Dania Bacardi; Indalecio Feria; Amilcar Ramirez; Karelia Cosme; Pedro López Saura; Maricel Quintana; Verena Muzio; Ricardo Bringas; Marta Ayala; Mario Mendoza; Luis E Fernández; Adriana Carr; Luis Herrera; Gerardo Guillén
Journal:  Front Oncol       Date:  2019-02-25       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.